Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "GIMAP1-GIMAP5 readthrough" refers to an mRNA transcript generated by transcriptional readthrough between the adjacent GIMAP1 (GTPase, IMAP family member 1) and GIMAP5 (GTPase, IMAP family member 5) genes. These genes encode small GTPases involved in immune cell signaling, but the readthrough product does not encode a recognized or functional protein. Its biological or therapeutic significance is not established, and it is not considered a therapeutic target or a validated gene product. The actual functional proteins, GIMAP1 and GIMAP5, are small GTPases with important roles in immune function and cell survival, particularly in T cells. However, the readthrough entity itself does not have an established role in any biological process, known disease, or drug interactions, and is likely included in databases primarily as a transcriptional annotation or artifact. If you are seeking information about the functional GIMAP1 or GIMAP5 proteins, those should be queried directly as they are well-characterized immune regulatory GTPases with distinct roles and molecular classification.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GIMAP1-GIMAP5 readthrough (GIMAP1-GIMAP5).